Researchers at Penn State University have found a potential mechanism for how breast cancer cells spread to other areas of the body. The results, published in the November issue of the journal Advanced Science, could change the way cancer is treated and open the door for new research pathways.

Breast cancer is the second-most common type of cancer in women in the U.S., aside from skin cancer, according to the American Cancer Society: one in eight U.S. women are expected to get diagnosed during their lifetime. It’s also the second-leading cause of cancer death in women, aside from lung cancer, and Non-Hispanic Black women are more likely to die from breast cancer than white women.

Although death rates have been decreasing, likely due to earlier cancer detection from advancing technologies, metastasis is the leading reason for cancer mortality. Once breast cancer spreads to other organs, the survival rate drops from 90.8% to 30%, according to National Cancer Institute data from 2013–2019.

Erdem Tabdanov, an assistant professor in the Department of Pharmacology at Penn State College of Medicine in Hershey, teamed up with colleagues including Amir Sheikhi, an assistant professor of chemical engineering at the university’s College of Engineering, to create a device that partially mimics living tissue and the tumor environment. Tabdanov said Sheikhi’s scaffold device was “the perfect fit” for their study, as it allowed them to model a living tissue to see how cells respond.

Advertise with us

The project also included scientists from the University of Rochester, Georgia Institute of Technology, Emory University and the Food and Drug Administration, and was funded in part by the FDA and the National Heart, Lung & Blood Institute.

What they found surprised them. “In this study, we showed if you block a specific protein, you can impair the movement of breast cancer cells,” said Sheikhi.

That specific protein is called dynein, a vital motor protein that helps transport cellular cargo along a cell's microtubules, like a train on a track. Cells are incredibly dynamic, and it was already known that proteins that make up their inner skeletons quickly shorten and lengthen to facilitate cell movement.

The researchers discovered that dynein was indispensable in the spread of cancer cells to nearby tissues. They confirmed this by adding chemicals that blocked dynein, and the cells couldn’t move.

“Instead of killing the cells, we are paralyzing them,” said Sheikhi.

Advertise with us

The researchers say it is the first time that dynein has been identified as playing a role in cancer cell movement.

Ioannis Zervantonakis, an assistant professor at the University of Pittsburgh Swanson School of Engineering and a member of UPMC Hillman Cancer Center, said the study was interesting and that it used a novel lens to better understand how cells move.

“The associations of the described molecular mechanism involving dynein are very encouraging and, in future studies, it will be critical to investigate the role of this molecule in non-cancer cells,” said Zervantonakis, who was not part of the study.

Another important component of the study: the levels of dynein in people with breast cancer. Using a database called the Human Protein Atlas, the researchers examined patient cancer prognoses and levels of molecules that regulate dynein. They found that higher levels of these dynein-related molecules predicted the aggressiveness of a patient’s cancer and, further, those patients experienced a lower survival rate.

This could be because of dynein’s role in helping cancer cells adapt to the tumor environment, which is confined, claustrophobic for cells inside. Sheikhi described his device as akin to a swimming pool filled with beach balls — tough to move around, but still possible.

Advertise with us

It’s “mechanically tortuous” for cells to migrate, explained Tabdanov, so they rely on the dynein apparatus. The cells become deformed and stretch out, without breaking or dying, like an octopus flattening out and squeezing through a tiny slit in a rock, allowing them to travel to other parts of the body.

Douglas Robinson, a professor of cell biology at the Johns Hopkins School of Medicine who specializes in studying cells’ internal structure, or cytoskeleton, and cell shape as it relates to disease, said the Penn State study is consistent with what he has been researching in his lab. He was not involved in the study.

“We’ve found that every cancer had at least one of these [skeletal] proteins present,” said Robinson. “When you have elevations of these proteins, they’re also poor prognostic indicators.”

In one 2021 review article, Robinson and his colleagues said the proteins involved in mechanical stresses and that help instate cell structure are a “goldmine” for cancer therapy, because they’re often altered or faulty in cancerous cells. This signals — as with dynein and cancer prognosis — a potential red flag for metastasis, in multiple cancer types.

The Penn State paper succeeded in recognizing the complexity and moving parts that make up a cell’s microtubule system, said Robinson, and that there could be many theories for this detected movement along the cell train tracks and the subsequent cell propulsion outside the tumor.

Advertise with us

The Penn State discovery could lead to a new market for cancer therapy that specifically targets certain motor proteins and “paralyzes” them, as Sheikhi, Tabdanov and others accomplished in their tissue model, to prevent metastasis.

“We are working on identifying the new targets,” said Tabdanov. “Exactly how is the question of future research.”

A new cancer therapy for humans based on this research is still a ways out: They still have to test this theory in animal models and then in humans, all the while identifying ways to safely target dynein and related molecules without hampering other crucial cellular processes, like cell division.

Like most of the scientific process, creating new drug therapies won’t exactly be straightforward.

“With inhibiting myosin and dynein, the problem is that they also have tumor-suppressant properties,” said Robinson. “And dynein is really important in cell division and mitosis,” he said. “If cells can’t divide, we’ve now added a sensitivity and potentially destabilized the cells.”

Advertise with us

“The good news is that there are many potential targets,” said Tabdanov. “It is very cool to stumble upon something new.”

Sheikhi said that developing and curating the cancer treatment to target specific cells could be a good next step when thinking about treatment to accompany this research.

“We do not want to impact healthy cells,” he said. “If we could selectively target dynein in cancer cells, this could be a significant improvement in cancer therapy.”

Hanna Webster: hwebster@post-gazette.com